SCLX NASDAQ
Palo Alto, CA 94303
US
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ma Stephen Hoi | P-Purchase | 650,000 | $1.20 | 2026-04-17 |
| Ji Henry | S-Sale | 650,000 | $1.20 | 2026-04-17 |
| Ji Henry | P-Purchase | 3,250,000 | $1.20 | 2026-04-16 |
| Scilex Holding Co | S-Sale | 9,657,300 | $0.54 | 2025-12-30 |
| Scilex Holding Co | S-Sale | 7,310,984 | $0.66 | 2025-12-29 |